Mundipharma International Ltd., of Cambridge, UK, said new data from three Phase III studies showed that flutiform, a combination of fluticasone propionate, an inhaled corticosteroid and long-acting beta2-agonist formoterol fumarate improved lung function and effectively controlled symptoms across different asthma severities in adolescents and adults.